Month: August 2011

The future availability of medicines orphans and ultra huérfanos will be compromised if it applies the cost saving measure announced by the Minister of health, social policy and equal.

|

the future availability of medicines orphans and ultra-huérfanos will be compromised if it applies the cost-saving measure announced by the Minister of health, social policy and equality.

AELMHU is positioned before the savings measures announced by the Government at the meeting of the plenary of the Interterritorial Council of the SNS

-the discount of 15% of the price of the innovative medicines that will take more than 10 years in the market and which do not have generic, applied to the orphan drugsit seriously jeopardizes the future availability of medicines indicated for the treatment of patients with rare and ultra-raras diseases.


Spain, 2011-July the Association Spanish of laboratories of medicines orphans and Ultra-Huérfanos (AELMHU), formed by companies that investigate, develop and market medicines for the treatment of rare and ultra-raras diseases, expresses great concern the extent of reduction of 15% of the price of the innovative medicineshave been more than 10 years in the market and that they are not generic. Apply this discount to medicines orphans and ultra-huérfanos, the future availability of these drugs (indicated for the treatment of patients with rare and ultra-raras diseases) will be seriously compromised.

AELMHU believes that, if the Government decides to implement this measure of reduction in the area of rare diseases, will be serious danger the future ability of companies to continue investing in the research needed for the development of new medicines to meet the health needs of these patients. With this measure, the Government would not recognizing the disproportionate negative impact that a new cut will have on the development of orphan medicinal products. In contrast, it should be noted and be aware of the savings for the health system will be minimal since due to the low prevalence of rare diseases, spending on orphan drugs and ultra-huérfanos in the health budget is negligible.

It should also be noted that many of the companies that market orphan drugs are newly formed, very small in terms of its infrastructure and even some of them have a marketed product. These companies invest and continue to invest in r & d in Spain. For this reason, a reduction in this area would be a serious threat to the viability of these enterprises, engines of research and development of new medicines for diseases without therapeutic alternatives.

Orphan drugs already suffered a discount in the price of 4% (RD 8/2010 of urgent measures for the control of the public deficit). An additional measure of lowering of prices of medicines orphans and ultra-huérfanos would be a direct conflict with the efforts made over the past decade, both European and national, to not recognize rare diseases, and drugs orphans who deal with, as a social priority that deserves a unique and specific treatment.

The creation of a selection of medicines Committee composed of experts from the ACS. should not result in an increase in the time in which a drug orphan becomes available in the market, which would run counter to the processes of rapid authorisation which is granted to these drugsdue to the fact that patients do not have any alternative therapy available.

The national health system must ensure to maintain support in the area of rare diseases with the aim that produce an efficient investment that will allow to have an increasing flow of drugs patients innovative orphans. Therefore, we firmly believe that the orphan drugs and ultra-huérfanos should be excluded from this price cut in the innovative medicines that will take more than 10 years in the market.

Medicines orphans and ultra-huérfanos

According to the definition of the European Union (EU), rare or uncommon diseases are those debilitating, chronic or life-threatening diseases affecting less than 5 per 10,000 inhabitants. Within this group are the disease ultra-huérfanas, which are those that affect less than 1 per 50,000 inhabitants. For many years the Group of patients with rare diseases not has been available since effective treatments that, under normal market conditions, the process of r & d of orphan medicinal products is not profitable for the pharmaceutical industry, due to the low number of patients affected. Therefore Regulation EC 141/2000 of the European Parliament was adopted in the year 2000 and of the Council with the aim of stimulating the development and marketing of orphan medicinal products, intended to diagnose, prevent or treat rare diseases. In addition, the European Commission has designated rare diseases as one of the priorities of health policy in the field of public health within the seventh framework programme. Also, rare diseases are still a priority for action within the programme of public health 2008-2013.

This whole set of European regulations applied by each of the Member States, has achieved the goal of promoting research in areas unattractive from the point of view of profitability, fact which has led to the commercialization of 62 orphan medicinal products. These efforts must, without doubt, continue since there are thousands of rare and ultra-raras diseases without any authorized treatment.

Read More

The Congress of pharmaceutical care show pharmacists to disseminate their research.

|

of pharmaceutical care Congress will teach pharmacists to disseminate their research.

VII Congress of pharmaceutical care – Pharmaceutical Care

-workshop ‘ dissemination of results of research in AF ’ put on the table the shortcomings of the communications made by pharmacists and give participants databases to publish their results.

-bugs in writing, barriers with the language, little bibliography, or lack of knowledge of the protocols are some of the main fault.

– “ unlike doctors, pharmacists do not receive specific training, which is why we need base ”, said Jose Carlos Andres, pharmacist community and head of the workshop.

-the National Congress of pharmaceutical carethat organizes the Pharmaceutical Care Foundation, will take place on September 28 to October 1 in Vigo.

Vigo, 2011-July The presentation of the results of an investigation is an essential part if not all the work to fall on deaf ears. There are three ways to disseminate the projects: the scientific article, poster or oral communication, the latter usually in congresses, conferences or seminars. In pharmacy research are not as prolific as in the medical sector, but there is not much communication in the same culture. In fact, most research fails in its communication, either due to ignorance of the copyright or for errors in the forms of presentation.

With the intention of going to eradicating this stigma that exists in the dissemination of the research carried out in the field of pharmacy, the National Congress of pharmaceutical care, Pharmaceutical Care Foundation organized in Vigo between 28 September and 1 October 2011It will offer a workshop to teach how to correctly communicate their research to pharmacists. “ Is a very practical workshop, in which we are going to give the basis for developing a good communication and its transformation into a scientific article ”, said Jose Carlos Andres, pharmacist community and head of the workshop. Add to “ unlike doctors, pharmacists have no specific training on research, which is why we need base ”.

The workshop will be based mainly in the identification of gaps with which accounts the studies to be broadcast as the incorrect wording, the little literature or of the language barrier. “ These last two are often complementary, because that lack of knowledge of English prevents many see bibliography in that language, which is a major waste of information ”, says Carlos Andrés. Likewise, the participants will also see what the most appropriate tools for developing a good Startegy of disclosure, and how to apply them. “ There are things that seem as simple as creating a powerpoint, not everyone knows them; and that, for example, is fundamental to present an oral communication ”.

Another of the problems when it comes to disseminating research is the limited number of communications in congresses that turn into articles published in specialized magazines. In the absence of the necessary training for the publication of an article, many presentations get stuck in the poster or oral presentations of the Conference. According to a published study on the Pharmaceutical Care Spain magazine, in which participated the José Carlos, in fact, only 15 per cent of communications at congresses have just published in specialized media. “ The low proportion of communications in congresses of AF and community pharmacy which are then published can influence the consolidation of the community pharmacy research; increase that percentage will depend rather on the quality of the submitted work, a task which is in the hands of the scientific committees of congresses and, above all, of the researchers themselves ”, explains the pharmacist.

Read More

About 500 million people worldwide are infected with hepatitis B or C virus and most unknown

|

500 million people worldwide are infected by the virus of hepatitis B or C and the majority ignores

Yesterday was held the Viral Hepatitis day world under the motto “ don’t hepatitis problems your life. Get to know her. Her face ”,

-the reasons for their lack of diagnosis are that 40% of infected patients do not belong to any of the groups at risk and that the majority of persons infected acute form does not have any symptoms

-experts recommend that, at the slightest suspicion of having been in contact with infected people, must attend the Health Center for the diagnosis of hepatitis test, both (b) as (c)

– in the case of hepatitis C stresses that it is a disease that can cause long-term major liver problems, from the development of cirrhosis and cancer to the death for them

-the treatment of chronic hepatitis C will change with the adoption of new treatments that, together with the usual standard therapy will increase the possibility of eliminating the viral infection in approximately 70% of patients. In this sense, the rescue of not answering patients new treatment options will be possible to

Madrid, July of 2011- hepatitis is a condition that continues still very prevalent, affecting one in twelve people in the world. In other words, that it there are about 500 million affected by the virus B and C of this disease. In particular, in our country, it is estimated that, approximately, 600,000 people are infected by hepatitis C.

All these data are of great social and medical importance that only some of these patients are treated because the majority are unaware they are infected. The fundamental reasons that lead to this fact, says Dr. John of la Revilla, Deputy of the service of hepatology of the Hospital Universitario iron gate are “ on the one hand, is an infection that has a few well known transmission routes but where 40% of infected patients does not belong to any of the risk groups for Intuit that they suffer from the disease. On the other hand, the fact that most people who become infected in acute form not present any symptoms also contributes to the difficulty for their diagnosis and the further expansion of the disease ”.

In this sense, the DRA. Immaculate Fernández Vázquez, attached Hospital 12 de Octubre Hepatology service, has an impact on stress, “ while the number of diagnosed patients is increasing in recent years, yet many cases are undiagnosed. For this reason, it is important that, even taking into account the asymptomatic nature of the virus, at the slightest suspicion of having been in contact with infected people call the Health Center for the diagnosis of hepatitis test, both (b) as (c) ”.

Under this circumstance, acquired ownership all campaigns and measures to be taken to create awareness of the need to diagnose patients and inform them, professionally, of everything that involves hepatitis.

For this reason, the Spanish Association of patients with Hepatitis C (AsoEEHC), takes many years working for the benefit of those affected and their families, as well as to promote the identification of new affected so that they receive advice and treatment as soon as possible. “ Dates as of today, where we celebrate the world Viral Hepatitis day, have as objective raising the general public about this disease so as to explain the risks of contagion and a late. diagnosis also maintain our role as informative source for all those affected and their families providing them with all the new data and developments concerning his illness ”, explains its President, Pedro Manuel Castelló.

Numerous social activities are being developed at Spain on the occasion of this day, which this year takes place July 28 to pay tribute to the birth of the winner of the Nobel Prize, Prof. Blumberg, discoverer of the hepatitis b virus “ La AsoEEHC has been commissioned to organize informative tables in different cities of our country as SevillaValencia, Toledo, Albacete, Murcia and Tenerife, among others ”, says Amparo Gonzalez, Coordinator of the AsoEEHC. “, Is being held a day of open doors to patients and their families in the lounge of acts of the Ministry of health, Social policy and equality with the participation of prestigious experts and personalities from politics as Rosa Ramírez Fernández, Deputy Director General of health promotion and epidemiology of the Ministry of healthSocial policy and equal ”, adds Amparo Gonzalez.

“ Don’t hepatitis problems your life. Get to know her. Her face ”, is the motto of this year this is because it should not be forgotten that hepatitis may have serious consequences on the persons concerned. In particular, in the case of hepatitis C, la Revilla Dr. reveals that “ can cause long-term major liver problems, from the development of cirrhosis and cancer to the death for them ”. But the expert stresses that “ if you get a diagnosis and initiation of treatment in the upstream of the disease, rather than develop significant liver damage, the chances of cure of the infection, and therefore the clear improvement of the prognosis of the disease in the long term are much higher and with important expectations ”.

In this regard, Dr. la Revilla as DRA. Fernández Vázquez coincide in highlighting the treatment of chronic hepatitis C is going to change with the adoption of new treatments that, together with the usual standard therapy, will increase the possibility of eliminating the viral infection in approximately 70% of patients. In this sense, the rescue of not answering patients new treatment options will be possible.

you can be infected?

There are a number of risk factors that facilitate the spread of the virus of hepatitis C in the blood. When you have been exposed to any of them, it would be advisable to perform a blood test:

• tattoos or piercings
• intranasal cocaine use
• blood transfusions prior to 1992
• sharing of syringes for drug
• dental interventions in countries in which not be spayed correctly material
• workforce risk
• share toilet fixtures or other objects that may have been contaminated with blood.

Read More

The CECOVA calls for a regional standard to regulate the obligatory use of materials of biosecurity to prevent accidental puncture

|

the CECOVA calls for a regional standard to regulate the obligatory use of materials of biosecurity to prevent accidental puncture

Ávila defends “ outpatient follow-up of liver patients that frequent, face-to-face or telephone, contact achieves that, before a secondary effect, the patient not interrupted treatment ”

Valencia, 2011-July the Council of nursing in the region of Valencia (CECOVA) and the colleges of nursing in ValenciaCastellón and Alicante recalled the occasion of the celebration of world day against Hepatitis, “ the need for autonomous regulations governing the compulsory use of antipinchazos devices for the safety of health care professionals and patients through the acquisition of bio-safety materials that minimize the risk of contagion in 85 per cent and the gradual eliminacióunsafe devices n ”.

In this regard, professional nursing organizations proposed to the Ministry of health that anticipates the transposition of the EU directive for the prevention of injuries caused by sharp and stabbing in hospital and healthcare sector instruments published on June 1 in the Official Journal of the European Union (OJEU) which requires Spain and the rest of Members to use these devices before May 11, 2013.

In this sense, Collegiate Nursing organizations claimed that “ the nurses were victims of 46 per cent of the accidental puncture that occur with the consequent risk of transmission of communicable diseases in this way such as AIDS or hepatitis ”. In addition, they recalled that in Spain, 10% of the accidental puncture of nurses occurs when they are attending a patient carrier of hepatitis C; 5 per cent when they attend a patient carrier of the virus of human immunodeficiency (HIV); and 2% with patients carriers of hepatitis B.

The President of the CECOVA, José Antonio Avila Olivares, explained that “ though five Spanish autonomous communities (Madrid, Castile – La Mancha, Balearic Islands, Galicia and Navarra) have legislation that requires the use of materials of the Comunitat Valenciana, which has been a pioneer in awareness, since 2002, through the Working Group in the CECOVA biohazards and biosafetyIt may not be outdone and he should soon develop a standard to support the use of antipinchazos devices ”.

A total of five Spanish communities have already been developed gradually since 2005 a set of rules to regulate the mandatory use of these devices in their respective health systems and, thus, the President of the CECOVA found that the Comunitat “ has been pioneer in the use of materials of biosafety neither can nor should be left behind in the adoption and development of effective legislation for the establishment of measures protection and security of health professionals so that, where an accident occurs, it is not cause of any kind of infection ”.

Liver patients outpatient follow-up

On the other hand, with regard to the role of nursing professionals in caring for patients with viral hepatitis, the CECOVA highlighted the importance of ambulatory monitoring of liver patients, explained Jose Antonio Avila, “ frequent, face-to-face or telephone, contact achieves that, faced with a side-effectthe patient not interrupted treatment because you do not know the significance of the effect, but will see the nurse about this symptom ”.

Thus, part of the work of ambulatory care focuses on patient control once it has already received the discharge and in this activity specialists understand that telephone monitoring allows you to create a link between doctor, nurse and patient that conveys more security to the patient and improves the control of the symptoms presented. The work done by nurses in these units of hepatology focuses on care, care and follow-up of liver patients, both in the consultation over the phone.

Read More

Roche includes a section for patients in their new website on hepatitis C.

|

roche includes a section for patients in their new website on hepatitis C.



– pharmaceutical company provides access to users through a very intuitive and easy to remember website using the name of the disease.

– a new paragraph to the general public can consult information on Hepatitis C news, articles of interest, relevant links, glossary of terms and information facilities.

– this portal shows the willingness of Roche to further research and progress in the treatment of Hepatitis C as well as disseminate knowledge of this pathology.

Madrid, July of 2011- Roche, after launching its website www.hepatitisc.es, includes in it a new section to patients. This tool, so far only offered content for health professionals, adds a section to the general public where to consult information about Hepatitis C news, articles of interest, relevant links, glossary of terms and general information. A new area open to the population whose goal is to extend knowledge about this disease and the different factors that affect it.

in this section, aimed at patients, helps the user General information on Hepatitis C ranging from diagnosis and follow-up tests, to tips for living a life healthy, measures to prevent the spread and what implications that may have this disease in daily life and long term health. Web site will also host other content such as, articles of interest, news and links relevant.

this initiative reflects the will of Roche to continue researching and advancing the science of Hepatitis C, bearing in mind, always in the first instance, to patients and their families as key players and stakeholders to promote maximum awareness about this disease.


about hepatitis C.

hepatitis C virus is known as the ‘ silent epidemic ’. The prevalence of this disease data place it as one of the epidemics of this century, which Spain affects about 800,000 Spaniards. The main causes of death associated with hepatitis C are the cirrhosis of the liver (in 35% of cases) and cancer of the liver (in 32% of cases).

roche, based in Basel (Switzerland), is a leading international company in the sector diagnostic, which prioritizes research and pharmaceutical health in areas. As the largest company Biotech in the world, innovative products and services for early detection, prevention, diagnosis and treatment of diseases, Roche contributes on various fronts to improve health and quality of life of people. Roche is the world leader in medicines and Diagnostics for cancer and transplantation, as well as a leader in Virology; It also operates in other major therapeutic areas such as autoimmune, inflammatory and metabolic diseases and central nervous system.



Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips